BREAKING NEWS 'Do not eat' alert issued as major supermarket recalls much-loved sauce over deadly contamination
A popular Chinese chilli sauce has been urgently recalled after it was found to contain undeclared peanuts—posing a potentially fatal risk to allergy sufferers.
Laoganma Black Bean Chilli Sauce, sold in 280g jars, is a cult favourite among food lovers and widely available in Asian supermarkets, independent grocers and online at retailers including Yau Brothers, Longdan and Japan Centre.
It is also stocked by some major supermarkets, including Sainsbury's, where it features in the world foods aisle.
Distributor Fortune Foods Ltd has issued a recall of batch code 18232 with a best-before date of 8 March 2026.
The affected product 'contains peanuts which are not mentioned on the label', according to an alert issued last night by the Food Standards Agency (FSA).
'If you have bought the above product and have an allergy to peanuts, do not eat it,' it warned. 'Instead return it to the store from where it was bought for a full refund.
Fortune Foods 'is recalling the above product from customers and has been advised to contact the relevant allergy support organisations, which will tell their members about the recall,' the agency added.
Peanut contamination can be fatal for allergy sufferers—exposure to just traces is enough to kill. More to come...
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
4 hours ago
- Telegraph
Indonesia to be vaccine self-sufficient by 2037, says health minister
The UK has just announced a 40 per cent real terms cut to its funding for Gavi, the global vaccine alliance, but Indonesia and many other developing countries are investing – and in many respects that is how it is supposed to be. In an exclusive interview with the Telegraph, Budi Gunadi Sadikin, Indonesia's health minister, said he aimed to make the country 'self-sufficient' in vaccine production by 2037. The lesson of the Covid pandemic was that no large country, including Britain, could rely on others in a global health emergency, he said. 'Every country with a very large population, they need to have their own vaccine [production] for health security, for healthcare system resiliency,' he said. Recalling that Indonesia and Britain had relied on India for Covid vaccines, only to see exports blocked when demand in India spiked, he added: 'We cannot put the lives of 280 million Indonesians at risk by depending on other countries when the next pandemic happens.' Mr Sadikin, a former banker with a sense of realpolitik that is rare in global health, stressed that he was not dismissing cooperation with other countries or blaming India, but emphasising the importance of national autonomy and self-reliance. 'Everybody wants to protect their own people, which is understandable,' he said. 'If you are a politician in India, two billion people will force you to do that. It is democratically understood.' Indonesia is Southeast Asia's largest economy and the world's third most populous country after India and China. It is currently classed as an 'upper middle income' country and is predicted to be the world's fourth largest economy by 2045. Already it is ranked seventh in terms of GDP purchasing power parity – three rungs ahead of the UK – and a recent survey found that more people report themselves to be 'thriving' in Indonesia than any other country in the world. Last week Mr Sadikin hosted a summit in Bali where healthcare leaders plotted a path to the global elimination of cervical cancer – the first cancer likely to succumb to a vaccine. The aim of the global WHO's Cervical Cancer Elimination Initiative is to wipe out the disease through a strategy focused on vaccination, screening, and treatment. Mr Sadikin said that cervical cancer remains the second most lethal cancer among women in Indonesia after breast cancer, killing some 60,000 women a year, or 'one death every 35 minutes'. The country's National Cervical Cancer Elimination Plan, launched in 2023, has already achieved over 90 per cent HPV vaccination rates for girls through a schools based programme. The country is also now making the jab available for women aged 21-26 who have missed out. Mr Sadikin said increased availability of the vaccine – which has until recently been limited by supply and dosing constraints – would also be extended to boys in Indonesia to protect against HPV related head, throat and neck cancers from 2026. He added that there was little or no residence to HPV vaccination in Indonesia, a majority Muslim country. 'Indonesian women are very receptive, very receptive, compared with other vaccinations,' he said. 'My observation, my first hypothesis, is they know it can save their life. Second, the vaccines were available before but it was very expensive'. It created a feeling of 'FOMO', or fear of missing out, he added. Indonesia is also gearing up to become something of a regional vaccine superpower and now has three domestic manufacturers. The biggest firm, Biofarma, produces vaccines against measles, polio and hepatitis B and will soon become a major supplier of HPV vaccine via a technology transfer deal with MSD, the international arm of Merck. Biofarma also makes antivenoms for snakebite. Snakes such as pit vipers and cobras are common across many of the 17,500 islands in the Indonesian archipelago. 'MSD is deeply committed to the global elimination of cervical cancer and prevention of certain other HPV related cancers, including in low- and middle-income countries where the burden is highest,' said Dr Priya Agrawal of MSD. 'The technology transfer with MSD for HPV vaccines has allowed us to make our own vaccines for our own country,' added Shadiq Akasya, CEO of Biofarma. 'This will save many lives, accelerate elimination of cervical cancer, and support the aims of national health security.' Bolstering a 'heavenly investment' Mr Sadikin put Indonesia's position at the top of the 'thriving' league down to the relaxed character and pace of life for which places like Bali are famous for. 'We still work pretty hard but we are not as ambitious and determined and greedy for money as some,' he said. 'We are very laid back, we are happy with what we have.' Mr Sadikin, who is religious, has a relaxed style but is no slouch. He made a fortune in banking and now says he is dedicating himself to health. 'I have more than enough earthly investment but I don't have enough heavenly investment,' he said. 'If I save 60,000 women from cervical cancer, God will definitely remember that. It's my dividend, my deposit, for the afterlife'. Yet the skills Mr Sadikin learned as a banker are now in huge demand in the area of global health as international aid budgets are cut. They are skills that are making him popular across the sector – perhaps popular enough to tempt him to run as the next WHO director general when Dr Tedros Adhanom Ghebreyesus steps down in two years time. 'Historically, you can easily check that our enemy, the one that kills most human beings, is the pathogen,' he said. And the trick to raising money for health was to 'make the right investment case'. 'My advice to all the health ministers, my colleagues, is that there is a huge amount of money floating around in the world. You just need to know where to knock on the door.' He added: 'If global health needs more finance people like me – people that can help get political leaders not to use your money to buy things to kill people but buy goods to save people – then 'yes', I think I can be pretty good at selling that concept across'.
The Independent
4 hours ago
- The Independent
No7 has dropped a half-price alternative to Laneige's sleeping mask – but which is best?
If you're on the Korean skincare hype, then you'll likely be across Laneige's famed sleeping masks. From the lip mask (£15.75, to the beauty buzzword 'cica' mask (£25.50, the brand is all about soothing overnight solutions. With the bouncy and firm mask (£32, Laneige uses collagen as an anti-ageing solution, combining hydration and nourishment to leave you with a healthy, springy skin barrier. But what if I told you another brand just launched an alternative for less than half the price? No7 has just released its good intent bouncy jelly mask (£14.95, which promises to soften, moisturise and give a dewy, 'glass skin' finish. The two products are very similar; the branding, pink packaging and springy translucent formulas mean there's little to split the two on paper. So the question is: how do they compare in practice? I got my hands on No7's good intent mask yesterday (24 June) to gauge my first impressions before its online drop. It wasn't, however, my first impression of the Laneige mask, with it launching more than a year ago in March 2024. Nonetheless, I acquainted (and reacquainted) myself with the treatments and set about comparing the two. Scroll on for my verdict. How I tested While No7's bouncy jelly mask recommends a minimum 10-minute use time, Laneige's stipulates overnight application. Considering my familiarity with the Laneige bouncy and firm formula, having used it overnight, I didn't revisit its 8-hour effectiveness. Instead, with one day to review No7's latest innovation, I gave both formulas around 20 minutes on clean skin: establishing a No7 first impression and refamiliarising myself with the Laneige. I followed both brands' instructions to apply a thin layer before removing with warm water and a hot flannel. I paid attention to the consistency of the masks on my skin, including any notable scents and textures, and then recorded the state of my skin afterwards. I looked to see any reflections of the brands' glowy and hydrating claims, and noted any positive or negative changes to the appearance and feel of my skin. Here's how I got on. Why you can trust IndyBest reviews Lucy Smith has several years of experience covering new beauty launches and has covered Laneige and No7 extensively. For the former, she's reviewed the watermelon lip mask, while for No7, she's explored everything from the velvet cloud blush to the soft glow cream bronzer.
The Guardian
5 hours ago
- The Guardian
Swarms of tiny nose robots could clear infected sinuses, researchers say
Swarms of tiny robots, each no larger than a speck of dust, could be deployed to cure stubborn infected sinuses before being blown out through the nose into a tissue, researchers have claimed. The micro-robots are a fraction of the width of a human hair and have been inserted successfully into animal sinuses in pre-clinical trials by researchers at universities in China and Hong Kong. Swarms are injected into the sinus cavity via a duct threaded through the nostril and guided to their target by electromagnetism, where they can be made to heat up and catalyse chemical reactions to wipe out bacterial infections. There are hopes the precisely targeted technology could eventually reduce reliance on antibiotics and other generalised medicines. The tiny devices are part of the expanding field of micro- and nano-robots for use in medicine. They have also been developed to deliver drugs and to remove bacteria from medical implants such as stents and hernia meshes. Experts believe they could be in clinical use for treating infections in bladders, intestines and sinuses in five to 10 years. Scientists in China, Switzerland, the US and the UK are developing more sophisticated versions capable of moving through the bloodstream. The latest development came from a collaboration of academics at the Chinese University in Hong Kong, and universities in Guangxi, Shenzhen, Jiangsu, Yangzhou and Macau. Researchers in the emerging field acknowledge risks include some of the tiny micro-robots being left behind after treatment which could cause longer-term side effects. Another potential problem, cited by technology experts, is public suspicion at the thought of welcoming robots into the human body and conspiracy theories arising around fears the robots could be activated without consent. The latest breakthrough, based on animal rather than human trials, involves magnetic particles 'doped' with copper atoms which clinicians insert with a catheter before guiding to their target under a magnetic field. The swarms can be heated up by reacting to light from an optical fibre that is also inserted into the body as part of the therapy. This allows the micro-robots to loosen up and penetrate viscous pus that forms a barrier to the infection site. The light source also prompts the micro-robots to disrupt bacterial cell walls and release reactive oxygen species that kill the bacteria. The study, published in Nature Robotics, showed the robots were capable of eradicating bacteria from pig sinuses and could clear infections in live rabbits with 'no obvious tissue damage'. The researchers have produced a model of how the technology could work on a human being, with the robot swarms being deployed in operating theatre conditions, allowing doctors to see their progress by using X-rays. Future applications could include tackling bacterial infections of the respiratory tract, stomach, intestine, bladder and urethra, they suggested. 'Our proposed micro-robotic therapeutic platform offers the advantages of non-invasiveness, minimal resistance, and drug-free intervention,' they said. Prof Sylvain Martel, director of the Nano Robotics Laboratory at the Polytechnique de Montréal in Canada, who was not involved in the research, said the science seemed effective. 'It's like a rocket that you can direct with a magnetic field,' he said. He predicted micro-robots could be available for treatments in three to five years but possibly not for another decade, as regulators still need to approve their use and the manufacturing processes, which differ from those of standard pharmaceuticals. 'The main advantage with micro-robots is the targeting,' Martel said. 'Instead of taking medicine that goes into the bloodstream and a small quantity goes to the right location, you can target.' He said the public would soon set aside any fears over the idea of having robotic devices in their bodies. 'Maybe at the beginning [they will be afraid],' he said. 'But they will get used to it pretty quickly.' Dr Andrea Soltoggio, a reader in artificial intelligence at Loughborough University, said: 'The public may be suspicious about non-biological objects like nano-robots being inserted into our bodies. It may even trigger conspiracy theories. 'But it is important to look at what nano-robots are designed for. In this case, we see an example of a targeted intervention to reduce or eradicate an infection with a localised action. 'Nano-robots' behaviour is often simpler and more targeted than many drugs and they could effectively complement a wide range of therapies.'
